Long-term Tolvaptan Treatment of Autosomal Dominant Polycystic Kidney Disease in Korea
- Author:
Ha Yeon KIM
1
;
Seung Jin LEE
;
Byung Ki KIM
;
Minah KIM
;
Eun Hui BAE
;
Seong Kwon MA
;
Soo Wan KIM
Author Information
- Publication Type:Case Report
- Keywords: Autosomal dominant polycystic kidney disease; Tolvaptan; V2-antagonist; Long-term outcome
- MeSH: Humans; Kidney; Korea; Liver; Male; Osmolar Concentration; Polycystic Kidney, Autosomal Dominant; Reference Values; Sodium; Young Adult
- From:Electrolytes & Blood Pressure 2018;16(2):23-26
- CountryRepublic of Korea
- Language:English
- Abstract: A 22-year-old male patient was diagnosed with autosomal dominant polycystic kidney disease (ADPKD). He received conservative treatment with an angiotensin-converting enzyme inhibitor. Two years later, oral therapy, consisting of 60 mg tolvaptan per day, was initiated. Compared with height-adjusted total kidney volume, the rate of kidney growth reduced significantly from 7.33% to 0.66% annually, since commencement of the tolvaptan therapy. The liver enzyme profile and serum sodium level and osmolality were constantly within normal ranges. In Korea, this is the first reported case of a patient with ADPKD who received tolvaptan treatment for more than 1 year. This case demonstrates that long-term tolvaptan treatment appears to be safe, well tolerated, and effective for ADPKD.
